Mon Dec 16 04:30:04 UTC 2024: **Hamps Bio IPO Oversubscribed on First Day, Offers Potential 79% Profit**
**MUMBAI, INDIA (December 16, 2024)** – The initial public offering (IPO) of Hamps Bio Limited, a pharmaceutical marketing and distribution company, has been fully subscribed on its first day, exceeding expectations. The IPO, priced at ₹51 per share, saw a remarkable 10.61 times oversubscription rate, attracting significant investor interest.
The ₹6.22 crore IPO, offering 12.2 lakh shares, closes on December 17th, with a listing date scheduled for December 20th. A robust grey market premium (GMP) of ₹40 suggests a potential listing price of around ₹91 per share, representing a potential profit of approximately 79% for investors.
Hamps Bio distributes a wide range of pharmaceutical products, including tablets, syrups, capsules, injectables, and nutritional supplements, through over 50 distributors and major e-commerce platforms like Amazon and Flipkart. The IPO proceeds will be used for [Insert details of how the funds will be used from the original text if available. Otherwise, remove this sentence.].
The company’s entry into the market coincides with strong growth in India’s pharmaceutical sector, and its focus on ethical marketing and distribution is expected to resonate with consumers.
While the high subscription rate and GMP indicate strong investor confidence, potential investors are urged to conduct thorough research or seek professional financial advice before investing. This article is for informational purposes only and does not constitute financial advice.
First Piper 